The inclusion criteria for patients in this study are based on the pathogenicity of the APC variants they carry, in contrast to other international studies where a clinical definition of FAP was used (> 100 adenomatous polyps in endoscopic studies). This evidence concerns the gene APC and Familial adenomatous polyposis.